HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisM. Juliana McElrath, Danilo R. Casimiro, Stephen C. De Rosa et al.|The Lancet|2008Cited by 699
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda Gray, James G. Kublin, Matsontso Mathebula et al.|The Lancet Infectious Diseases|2011Cited by 385
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams et al.|PLoS ONE|2011Cited by 137
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40